Monoclonal antibody therapy in cancer

When two is better (and considerably more expensive) than one

Gregory M Peterson, Jackson Thomas, Kwang C Yee, Sam Kosari, Mark Naunton, Inger H Olesen

Research output: Contribution to journalComment/debate

2 Citations (Scopus)

Abstract

WHAT IS KNOWN AND OBJECTIVE: It is 20 years since the US Food and Drug Administration approved the first successful monoclonal anticancer antibody, trastuzumab. The therapeutic utility of monoclonal antibodies in cancer is often limited by partial clinical responses and the development of tumour resistance. An expanding strategy, to be reviewed here, to overcome the limited response and resistance to monotherapy utilizes concurrent treatment with two synergistic monoclonal antibodies. COMMENT: Key examples include two monoclonal antibodies, each engaging a distinct site of human epidermal growth factor receptor 2 (HER2), in the treatment of breast cancer and a combination of antibodies to two distinct T-cell antigens for the treatment of melanoma. Here, we provide an overview of the rationale and evidence for using selected monoclonal antibodies in combination for treating some cancers, along with potential hazards, especially autoimmune-related toxicities. WHAT IS NEW AND CONCLUSION: Thorough research, the development of panels of biomarkers and individualization of therapy will be necessary to optimize the use of these combinations and minimize the substantial risk of overstimulating the immune system.

Original languageEnglish
Pages (from-to)925-930
Number of pages5
JournalJournal of Clinical Pharmacy and Therapeutics
Volume43
Issue number6
DOIs
Publication statusPublished - 2018

Fingerprint

Monoclonal Antibodies
Neoplasms
Therapeutics
Viral Tumor Antigens
United States Food and Drug Administration
Immune System
Melanoma
Biomarkers
Breast Neoplasms
T-Lymphocytes
Antibodies
Research

Cite this

@article{3ab459a12922412e9243d6bdbae528b1,
title = "Monoclonal antibody therapy in cancer: When two is better (and considerably more expensive) than one",
abstract = "WHAT IS KNOWN AND OBJECTIVE: It is 20 years since the US Food and Drug Administration approved the first successful monoclonal anticancer antibody, trastuzumab. The therapeutic utility of monoclonal antibodies in cancer is often limited by partial clinical responses and the development of tumour resistance. An expanding strategy, to be reviewed here, to overcome the limited response and resistance to monotherapy utilizes concurrent treatment with two synergistic monoclonal antibodies. COMMENT: Key examples include two monoclonal antibodies, each engaging a distinct site of human epidermal growth factor receptor 2 (HER2), in the treatment of breast cancer and a combination of antibodies to two distinct T-cell antigens for the treatment of melanoma. Here, we provide an overview of the rationale and evidence for using selected monoclonal antibodies in combination for treating some cancers, along with potential hazards, especially autoimmune-related toxicities. WHAT IS NEW AND CONCLUSION: Thorough research, the development of panels of biomarkers and individualization of therapy will be necessary to optimize the use of these combinations and minimize the substantial risk of overstimulating the immune system.",
keywords = "cancer, combination, immune checkpoint, monoclonal antibody, toxicity",
author = "Peterson, {Gregory M} and Jackson Thomas and Yee, {Kwang C} and Sam Kosari and Mark Naunton and Olesen, {Inger H}",
note = "{\circledC} 2018 John Wiley & Sons Ltd.",
year = "2018",
doi = "10.1111/jcpt.12750",
language = "English",
volume = "43",
pages = "925--930",
journal = "Journal of Clinical and Hospital Pharmacy",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "6",

}

Monoclonal antibody therapy in cancer : When two is better (and considerably more expensive) than one. / Peterson, Gregory M; Thomas, Jackson; Yee, Kwang C; Kosari, Sam; Naunton, Mark; Olesen, Inger H.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 43, No. 6, 2018, p. 925-930.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Monoclonal antibody therapy in cancer

T2 - When two is better (and considerably more expensive) than one

AU - Peterson, Gregory M

AU - Thomas, Jackson

AU - Yee, Kwang C

AU - Kosari, Sam

AU - Naunton, Mark

AU - Olesen, Inger H

N1 - © 2018 John Wiley & Sons Ltd.

PY - 2018

Y1 - 2018

N2 - WHAT IS KNOWN AND OBJECTIVE: It is 20 years since the US Food and Drug Administration approved the first successful monoclonal anticancer antibody, trastuzumab. The therapeutic utility of monoclonal antibodies in cancer is often limited by partial clinical responses and the development of tumour resistance. An expanding strategy, to be reviewed here, to overcome the limited response and resistance to monotherapy utilizes concurrent treatment with two synergistic monoclonal antibodies. COMMENT: Key examples include two monoclonal antibodies, each engaging a distinct site of human epidermal growth factor receptor 2 (HER2), in the treatment of breast cancer and a combination of antibodies to two distinct T-cell antigens for the treatment of melanoma. Here, we provide an overview of the rationale and evidence for using selected monoclonal antibodies in combination for treating some cancers, along with potential hazards, especially autoimmune-related toxicities. WHAT IS NEW AND CONCLUSION: Thorough research, the development of panels of biomarkers and individualization of therapy will be necessary to optimize the use of these combinations and minimize the substantial risk of overstimulating the immune system.

AB - WHAT IS KNOWN AND OBJECTIVE: It is 20 years since the US Food and Drug Administration approved the first successful monoclonal anticancer antibody, trastuzumab. The therapeutic utility of monoclonal antibodies in cancer is often limited by partial clinical responses and the development of tumour resistance. An expanding strategy, to be reviewed here, to overcome the limited response and resistance to monotherapy utilizes concurrent treatment with two synergistic monoclonal antibodies. COMMENT: Key examples include two monoclonal antibodies, each engaging a distinct site of human epidermal growth factor receptor 2 (HER2), in the treatment of breast cancer and a combination of antibodies to two distinct T-cell antigens for the treatment of melanoma. Here, we provide an overview of the rationale and evidence for using selected monoclonal antibodies in combination for treating some cancers, along with potential hazards, especially autoimmune-related toxicities. WHAT IS NEW AND CONCLUSION: Thorough research, the development of panels of biomarkers and individualization of therapy will be necessary to optimize the use of these combinations and minimize the substantial risk of overstimulating the immune system.

KW - cancer

KW - combination

KW - immune checkpoint

KW - monoclonal antibody

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=85055416522&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/monoclonal-antibody-therapy-cancer-two-better-considerably-more-expensive-one

U2 - 10.1111/jcpt.12750

DO - 10.1111/jcpt.12750

M3 - Comment/debate

VL - 43

SP - 925

EP - 930

JO - Journal of Clinical and Hospital Pharmacy

JF - Journal of Clinical and Hospital Pharmacy

SN - 0269-4727

IS - 6

ER -